Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

LLM 2021 | Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting

Ruben Niesvizky • 25 Oct 2021
LLM 2021
Multiple Myeloma Antibodies CAR-T

Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, discusses future strategies for consolidation therapy in multiple myeloma. Prof. Niesvizky explains that novel therapies including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy that have shown high efficacy in relapsed/refractory disease could potentially be used as an alternative to stem cell transplantation in the consolidation setting. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

More from Ruben Niesvizky

Key myeloma discussion topics at LLM 2021 2:51
Key myeloma discussion topics at LLM 2021
Ruben Niesvizky • 25 Oct 2021
Innovative treatment strategies for multiple myeloma 1:41
Innovative treatment strategies for multiple myeloma
Ruben Niesvizky • 25 Oct 2021
Using molecular techniques to define risk in patients with myeloma 1:22
Using molecular techniques to define risk in patients with myeloma
Ruben Niesvizky • 25 Oct 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals